血液透析管理

doi:10.16138/j.1673-6087.2021.01.001

摘要/Abstract

中图分类号:

R692

王莉. 血液透析管理[J]. 内科理论与实践, 2021, 16(01): 1-3.

参考文献 26

[1]	GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2020, 395(10225): 709-733. doi: 10.1016/S0140-6736(20)30045-3 URL
[2]	Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review[J]. Lancet, 2015, 385(9981): 1975-1982. doi: 10.1016/S0140-6736(14)61601-9 URL
[3]	Lok CE, Huber TS, Lee T, et al. KDOQI clinical practice guideline for vascular access: 2019 update[J]. Am J Kidney Dis, 2020, 75(4 Suppl 2): S1-S164.
[4]	Yu Y, Xiong Y, Zhang C, et al. Vascular access type was not associated with mortality and the predictors for cardiovascular death in elderly Chinese patients on hemodialysis[J]. Blood Purif, 2020, 49(1-2): 63-70. doi: 10.1159/000502941 URL
[5]	Lookstein RA, Haruguchi H, Ouriel K, et al. Drug-coated balloons for dysfunctional dialysis arteriovenous fistulas[J]. N Engl J Med, 2020, 383(8): 733-742. doi: 10.1056/NEJMoa1914617 URL
[6]	Xiong F, Tang H, Liu L, et al. Clinical characteristics of and medical interventions for COVID-19 in hemodialysis patients in Wuhan, China[J]. J Am Soc Nephrol, 2020, 31(7): 1387-1397. doi: 10.1681/ASN.2020030354 pmid: 32385130
[7]	Ajaimy M, Melamed ML. COVID-19 in patients with kidney disease[J]. Clin J Am Soc Nephrol, 2020, 15(8): 1087-1089. doi: 10.2215/CJN.09730620 URL
[8]	Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2[J]?. Am J Physiol Renal Physiol, 2020, 318(6): F1454-F1462. doi: 10.1152/ajprenal.00160.2020 URL
[9]	Roberts MA, Polkinghorne KR, McDonald SP, et al. Se-cular trends in cardiovascular mortality rates of patients receiving dialysis compared with the general population[J]. Am J Kidney Dis, 2011, 58(1): 64-72. doi: 10.1053/j.ajkd.2011.01.024 URL
[10]	Smyth B, Haber A, Trongtrakul K, et al. Representativeness of randomized clinical trial cohorts in end-stage kidney disease: a meta-analysis[J]. JAMA Intern Med, 2019, 179(10): 1316-1324. doi: 10.1001/jamainternmed.2019.1501 URL
[11]	Ajmal F, Probst JC, Brooks JM, et al. Freestanding dialysis facility quality incentive program scores and mortality among incident dialysis patients in the United States[J]. Am J Kidney Dis, 2020, 75(2): 177-186. doi: 10.1053/j.ajkd.2019.07.023 URL
[12]	洪大情, 何强, 蒲蕾, 等. 2011年度四川省血液透析患者死亡情况分析[J]. 中国血液净化, 2012, 11(10): 575-578.
[13]	Hong D, Wu S, Pu L, et al. Abdominal aortic calcification is not superior over other vascular calcification in predicting mortality in hemodialysis patients: a retrospective observational study[J]. BMC Nephrol, 2013, 14: 120. doi: 10.1186/1471-2369-14-120 URL
[14]	Ketteler M, Block GA, Evenepoel P, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update[J]. Ann Intern Med, 2018, 168(6): 422-430. doi: 10.7326/M17-2640 pmid: 29459980
[15]	国家肾脏疾病临床医学研究中心. 中国慢性肾脏病矿物质和骨异常诊治指南概要[J]. 肾脏病与透析肾移植杂志, 2019, 28(1): 52-57.
[16]	Li Y, Shi H, Wang WM, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study[J]. Medicine(Baltimore), 2016, 95(24): e3872.
[17]	Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease[J]. Am J Kidney Dis, 1996, 28(1): 53-61. pmid: 8712222
[18]	Zuo L, Wang M, Hou F, et al. Anemia management in the China dialysis outcomes and practice patterns study[J]. Blood Purif, 2016, 42(1): 33-43. doi: 10.1159/000442741 URL
[19]	Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019, 381(11): 1011-1022. doi: 10.1056/NEJMoa1901713 URL
[20]	林珍, 王池凤, 邓琼丽, 等. 信息化管理在我院血透护理中的应用[J]. 名医, 2020, (1): 294.
[21]	张宇, 米春香. 基于BS架构的血液透析患者排床管理系统开发[J]. 医学信息, 2020, 33(4): 20-22.
[22]	李占霞, 黄嘉琳, 倪洁, 等. 电子信息化管理系统对血液透析室护理人员心理资本、工作投入状况的影响[J]. 实用临床医药杂志, 2020, 24(8): 26-28.
[23]	张金霞, 丁晓仙, 陈益. 信息化管理系统在血透室专科指标监测管理中的应用体会[J]. 基层医学论坛, 2020, 24(3): 442-443.
[24]	施建文, 曹亮, 施春艳. 血液透析信息化系统方案设计与实践[J]. 世界最新医学信息文摘(连续型电子期刊), 2019, 19(73): 231-232.
[25]	Burlacu A, Iftene A, Jugrin D, et al. Using artificial intelligence resources in dialysis and kidney transplant patients: a literature review[J]. Biomed Res Int, 2020, 2020: 9867872.
[26]	Xie G, Chen T, Li Y, et al. Artificial intelligence in nephrology: how can artificial intelligence augment nephrologists' intelligence[J]?. Kidney Dis (Basel), 2020, 6(1): 1-6.

血液透析管理

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 14

编辑推荐

Metrics

本文评价

[1]	高健, 王德琴, 周永华, 缪娴静, 陈宇, 景鑫, 王艳. 血清生长刺激表达基因2蛋白和脂蛋白相关磷脂酶A2与维持性血液透析患者心血管事件的关系[J]. 内科理论与实践, 2022, 17(04): 295-300.
[2]	洪大情. 血液透析信息化建设[J]. 内科理论与实践, 2021, 16(01): 15-17.
[3]	汤荟, 张春. 新型冠状病毒病与肾脏替代治疗[J]. 内科理论与实践, 2021, 16(01): 4-9.
[4]	占志朋, 谢席胜, 张凌. 维持性血液透析合并难治性继发性甲状旁腺功能亢进患者甲状旁腺激素水平与骨密度的关系[J]. 内科理论与实践, 2021, 16(01): 45-48.
[5]	樊雪强, 刘鹏. 血液透析通路狭窄的发生机制及防治[J]. 外科理论与实践, 2019, 24(04): 289-292.
[6]	邹杨, 洪大情, 夏菊花, 何强, 李贵森,. 血清白蛋白与维持性血液透析患者心血管钙化的关系[J]. 内科理论与实践, 2018, 13(04): 218-222.
[7]	鲁嘉越, 占雅萍, 张伟明, 李萍, 刘上, 朱旻霞, 蔡宏, 倪兆慧. 维持性血液透析患者抑郁发生情况及相关因素分析[J]. 诊断学理论与实践, 2017, 16(04): 390-393.
[8]	李艳秀, 王勇, 左祥荣, 曹权,. 早期短时静脉-静脉血液透析滤过对重症急性胰腺炎病人合并急性肾损伤的治疗[J]. 外科理论与实践, 2012, 17(06): 673-677.
[9]	宦红娣, 张景红, 张军力, 陆春来, 陆蓓莉, 李萍, 杨峻, 吴晓梅, 杨黄,. 血液灌流对维持性血液透析患者高磷血症的影响[J]. 诊断学理论与实践, 2011, 10(03): 221-225.
[10]	丁小强, 吕文律, 邹建洲,. 血液透析患者长期预后及其影响因素[J]. 诊断学理论与实践, 2011, 10(03): 198-201.
[11]	袁自宏, 周健美, 姚少峰, 陈兵,. 不同钙浓度透析液对高磷血症血液透析患者钙磷代谢和血清胎球蛋白A水平的影响[J]. 内科理论与实践, 2008, 3(01): 41-44.
[12]	龚宇, 许化溪,. 血液透析患者肝素诱导的血小板减少症发病机制及诊治研究进展[J]. 诊断学理论与实践, 2007, 6(06): 551-554.
[13]	曹励欧,钱家麒,严玉澄,庞慧华,林星辉. 成年血液透析患者对重组乙型肝炎病毒疫苗的应答[J]. 诊断学理论与实践, 2004, 3(05): 70-71.
[14]	王朝晖,陈楠,朱萍,钱莹,沈平雁,汪关煜. 维持性血液透析患者乙、丙型肝炎病毒感染情况及原因分析[J]. 诊断学理论与实践, 2004, 3(01): 13-15.